Round 3 Clinical Project Selection Process
OTHER SPECIALTIES (NON-CANCER)
Investment is being directed by the Round 3 Clinical Project Investment Principles which build on Queensland Genomics Round 1 and Round 2, and have been approved by Queensland Health.
Round 3 Clinical projects may include a focus on patient cohorts and/or disease areas to build evidence in:
- precision medicine,
- pharmacogenomics, and/or
- population/preventative health.
Queensland Clinical Networks stream
Queensland Genomics is currently working with Queensland’s clinical networks to identify potential Round 3 clinical projects as a targeted expression of interest activity.
Potential projects will undergo the assessment process before review and recommendation by the Queensland Genomics’ Governance Oversight Group ahead of submission to Queensland Health Director-General for approval.
How do I apply?
Queensland Genomics is working with Queensland’s clinical networks to identify potential Round 3 clinical projects as a targeted expression of interest activity.
Due to the interest from the clinical networks, the reanalysis stream is no longer required.
Selection Process (Non-Cancer)
Round 3 Clinical Projects will be selected using a streamlined version of the Round 2 selection process:
- Targeted Expression of Interest (August-September)
- Project assessment considering Clinical Utility, Partnerships, Feasibility (September-October)
- Contracting and project start up (October-November)
The Round 3 clinical project selection process is underway from August to October 2019.
Queensland Genomics will prepare the Round 3 Clinical Projects Business Case for Governance Oversight Group endorsement in October 2019 prior to Director-General approval. Project contracting and start up will begin following Director-General approval.
All Round 3 projects must align to Queensland Genomics’ end date of 30 June 2021.
Essential criteria for clinical projects:
- Led by practising clinician in the relevant speciality
- Supported by relevant clinical network or multisite clinically led governance
- Occurs within a Queensland Health hospital or clinical setting
- Implementation or Innovation projects
- Partners with Pathology Queensland to further Pathology Queensland capability
- Aligns to the Round 3 Clinical Project Investment Principles, Genomics Adoption Framework and Queensland Genomics Objectives.
Highly desirable criteria for clinical projects:
- Leverages Queensland Genomics Round 2 investment to look at precision medicine applications that expand capability for analysis or reanalysis for pharmacogenomics and functional genomics with a diagnostics capability
- Established research partnership.
For more information
Email email@example.com with any questions about the Round 3 Clinical Project Selection Process.
To stay up to date on the Round 3 project selection process sign up for the Queensland Genomics eNewsletter.